Brain Res

1. SHARMA R, Pandey A, Agarwal R, Tripathi S, et al
   Network meta-analysis of migraine therapies: balancing efficacy and safety.
   Brain Res. 2025 Sep 17:149946. doi: 10.1016/j.brainres.2025.149946.
   

   >> Share

   
   

   
   Cephalalgia

2. THURAIAIYAH J, Christensen RH, Al-Khazali HM, Wiggers A, et al
   Overlap between perceived triggers, premonitory symptoms and symptom persistence across migraine phases: A REFORM study.
   Cephalalgia. 2025;45:3331024251364234.
   

   >> Share

   
   
3. ZHAI Q, Li H, Chen Q, Zhang N, et al
   Microglial TRPV2-mediated neuroinflammation promotes central sensitization through microglial polarization in a vestibular migraine mouse model.
   Cephalalgia. 2025;45:3331024251364753.
   

   >> Share

   
   

   
   Headache

4. LA N, Rattanapitoon SK, Rattanapitoon NK
   Cardiovascular risk considerations in triptan therapy for migraine: Reflections on the study by Peles et al.
   Headache. 2025 Sep 22. doi: 10.1111/head.15063.
   

   >> Share

   
   
5. LEE KH, Liang CS, Yeh PK, Tsai CK, et al
   Insomnia severity in migraine: The role of headache frequency, aura status, and comorbidities-A cross-sectional study.
   Headache. 2025 Sep 19. doi: 10.1111/head.15055.
   

   >> Share

   
   
6. EZZATI A, Fanning KM, Teichrow D, Urani A, et al
   Headache Assessment via Digital Platform in United States: Baseline study characteristics, diagnosis, and treatment patterns.
   Headache. 2025;65:1428-1438.
   

   >> Share

   
   

   
   Lancet Neurol

7. OIE LR, Wergeland T, Salvesen O, Gravdahl GRB, et al
   Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial.
   Lancet Neurol. 2025;24:817-827.
   

   >> Share

   
   
8. LEE MJ
   Revisiting candesartan: new evidence for an old option in migraine prevention.
   Lancet Neurol. 2025;24:802-803.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share